{
    "clinical_study": {
        "@rank": "45209", 
        "arm_group": [
            {
                "arm_group_label": "Hepatic patients", 
                "description": "patients with hepatic insufficiency"
            }, 
            {
                "arm_group_label": "Healthy Controls", 
                "description": "Healthy adults"
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum and urine"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "To test whether patients with hepatic insufficiency can tolerate one oral dose of\n      9-cis-retinoic acid and to test whether the metabolism of retinoic acid is altered."
        }, 
        "brief_title": "Single Dose of 9-cis-retinoic Acid in Hepatic Patients", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hepatic Insufficiency", 
        "condition_browse": {
            "mesh_term": "Hepatic Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Have biopsy verified hepatic insufficiency\n\n          2. Medically stable.\n\n          3. Ultra sonic examination of lever within the past 3 months\n\n          4. No pregnancy documented in women. use of anticonception during study and 1 month\n             after\n\n        Exclusion criteria:\n\n          1. Odd blood counts and samples not related to hepatic disease\n\n          2. encephalopathy (> grad II)\n\n          3. concomitant treatment with pharmaca that is metabolized by CYP3A4 in the liver.\n\n          4. Cardiac disease\n\n          5. Kidney disease\n\n          6. Epilepsia\n\n          7. Stroke\n\n          8. Esophagal bleeding\n\n          9. Severe ascites\n\n         10. HIV-positivity\n\n         11. Psychiatric disorder\n\n         12. Cancer\n\n         13. pregnancy or lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "10 patients with hepatic disease and 10 controls"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01891526", 
            "org_study_id": "2010-338", 
            "secondary_id": "Allitretinoin"
        }, 
        "intervention": {
            "arm_group_label": [
                "Hepatic patients", 
                "Healthy Controls"
            ], 
            "description": "Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure", 
            "intervention_name": "9-cis-retinoic acid", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Isotretinoin", 
                "Tretinoin", 
                "Alitretinoin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Metabolisation of 9-cis-retinoic acid", 
            "hepatic patients", 
            "investigation of urine and blood samples"
        ], 
        "lastchanged_date": "June 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gentofte", 
                    "country": "Denmark", 
                    "zip": "2900"
                }, 
                "name": "Gentofte Hospital"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Pharmacokinetics of a Single Dose of 9-cis-retinoic Acid (Alitretinoin, Toctino\u00ae) in Patients With Moderate to Severe Hepatic Insufficiency", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "The Danish National Committee on Biomedical Research Ethics, Denmark:", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Analysis on samples", 
            "measure": "A comparison of the metabolisation of retinoic acid in patients with hepatic insufficiency and controls", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01891526"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Gentofte, Copenhagen", 
            "investigator_full_name": "Frederik Gr\u00f8nlund MD DMSci", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University Hospital, Gentofte, Copenhagen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Gentofte, Copenhagen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}